Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Published on: Jan 7, 2025

Access insider insights from combined perspectives of clinical pharmacology, global regulatory considerations, and private equity investors on accelerating early development timelines to go/no go decisions and early proof of concept, without shortcuts. Parexel’s early phase team and EQT LifeSciences share best practices for combining sequential early phase studies into a single protocol.

Return to Insights Center

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Webinar

Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development

May 6, 2025

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Webinar

Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development

May 6, 2025

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Show more